243 related articles for article (PubMed ID: 27771290)
21. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.
Kohlmann A; Bacher U; Schnittger S; Haferlach T
Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312
[TBL] [Abstract][Full Text] [Related]
22. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes.
Abou Zahr A; Saad Aldin E; Barbarotta L; Podoltsev N; Zeidan AM
Expert Rev Anticancer Ther; 2015; 15(9):1019-36. PubMed ID: 26292903
[TBL] [Abstract][Full Text] [Related]
23. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
24. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
Zhang L; Padron E; Lancet J
Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
[TBL] [Abstract][Full Text] [Related]
25. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
Reinig E; Yang F; Traer E; Arora R; Brown S; Rattray R; Braziel R; Fan G; Press R; Dunlap J
Am J Clin Pathol; 2016 Apr; 145(4):497-506. PubMed ID: 27124934
[TBL] [Abstract][Full Text] [Related]
26. Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis.
Kunze K; Gamerdinger U; Leßig-Owlanj J; Sorokina M; Brobeil A; Tur MK; Blau W; Burchardt A; Käbisch A; Schliesser G; Kiehl M; Rosenwald A; Rummel M; Grimminger F; Hain T; Chakraborty T; Bräuninger A; Gattenlöhner S
Pathol Res Pract; 2014 Jun; 210(6):369-76. PubMed ID: 24674452
[TBL] [Abstract][Full Text] [Related]
27. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
Stankov K; Stankov S; Katanic J
Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
[TBL] [Abstract][Full Text] [Related]
28. Life after hypomethylating agents in myelodysplastic syndrome: new strategies.
Santini V
Curr Opin Hematol; 2015 Mar; 22(2):155-62. PubMed ID: 25603477
[TBL] [Abstract][Full Text] [Related]
29. [Treatment for myelodysplastic syndromes and future perspectives in the genomic era].
Maeda T
Rinsho Ketsueki; 2021; 62(8):1038-1049. PubMed ID: 34497190
[TBL] [Abstract][Full Text] [Related]
30. Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?
Chung SS
Curr Opin Hematol; 2016 Mar; 23(2):79-87. PubMed ID: 26825694
[TBL] [Abstract][Full Text] [Related]
31. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
Mohty R; Al Hamed R; Bazarbachi A; Brissot E; Nagler A; Zeidan A; Mohty M
J Hematol Oncol; 2022 Aug; 15(1):124. PubMed ID: 36045390
[TBL] [Abstract][Full Text] [Related]
32. Myelodysplastic syndromes in the United States: an update for clinicians.
Troy JD; Atallah E; Geyer JT; Saber W
Ann Med; 2014 Aug; 46(5):283-9. PubMed ID: 24716735
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Pophali P; Desai SR; Shastri A
Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
[TBL] [Abstract][Full Text] [Related]
34. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
[TBL] [Abstract][Full Text] [Related]
35. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
36. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
Duncavage EJ; Tandon B
Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cell transplantation for myelodysplastic syndrome.
Parmar S; de Lima M
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S37-44. PubMed ID: 19857589
[TBL] [Abstract][Full Text] [Related]
38. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
39. [Sequential acquisition of mutations in myelodysplastic syndromes].
Makishima H
Rinsho Ketsueki; 2017; 58(10):1828-1837. PubMed ID: 28978821
[TBL] [Abstract][Full Text] [Related]
40. Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT).
Trobaugh-Lotrario AD; Kletzel M; Quinones RR; McGavran L; Proytcheva MA; Hunger SP; Malcolm J; Schissel D; Hild E; Giller RH
Bone Marrow Transplant; 2005 Jan; 35(2):143-9. PubMed ID: 15558042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
